Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model-authors' response

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 634-635

  Siopi, Maria ^a   Mavridou, Eleftheria ^b   Mouton, Johan W ^b,c   Verweij, Paul E ^b   Zerva, Loukia ^a   Meletiadis, Joseph ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aspergillus fumigatus; PK PD parameter; Voriconazole

Indexed keywords

GALACTOMANNAN; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; DRUG MONITORING; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANIMAL; ASPERGILLOSIS; DRUG EFFECTS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HUMANS; VORICONAZOLE;

EID: 84922455228     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku484     Document Type: Article

References (11)

1. Denning DW, Ghnan N, Kwizera R et al. Comment on: Susceptibility breakpoints and target values for the therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother 2015; 70: 633.
2. Siopi M, Mavridou E, Mouton JWet al. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother 2014; 69: 1611-9.
3. Al-Saigh R, Elefanti A, Velegraki A et al. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model. Antimicrob Agents Chemother 2012; 56: 5321-7.
4. Chryssanthou E, Sjolin J. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration. J Antimicrob Chemother 2004; 54: 940-3.
5. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
6. Elefanti A, Mouton JW, Krompa K et al. Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother 2013; 57: 1625-31.
7. Elefanti A, Siopi M, Zerva L et al. Impact of the dosing frequency on azole's pharmacodynamics against Aspergillus fumigatus. In: Abstracts of the Fifty-fourth Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, DC, 2014. Abstract M456. American Society for Microbiology, Washington, DC, USA.
8. Seyedmousavi S, Meis JF, Bruggemann RJM et al. Pharmacodynamics of the new azole isavuconazole in an Aspergillus fumigatus mouse infection model (P1698). In: Abstracts of the Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2014. Abstract P1698.
9. Mavridou E, Bruggemann RJ, MelchersWJ et al. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010; 54: 4758-64.
10. Takemoto K, Yamamoto Y, Ueda Y et al. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy 2009; 55: 105-13.
11. Mouton JW. Pharmacokinetics and pharmacodynamics of azoles. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Informa Healthcare, 2007; 327-54.